Side Effects of Immunoglobulin Therapy
Immunoglobulin therapy causes side effects ranging from very common mild reactions (occurring in ~80% of patients) to rare but serious life-threatening complications (occurring in <1% of patients), with the severity and type varying significantly between intravenous (IVIG) and subcutaneous (SCIG) routes. 1
Classification by Severity and Timing
Mild Side Effects (Very Common: ~80% of patients)
Local reactions are the predominant side effect, particularly with SCIG:
- Pain, tenderness, swelling, and erythema at injection site 2
- Redness, swelling, and itching (most frequent with SCIG) 3
- These persist hours to 1-2 days after administration 2
- Important: Local reactions decrease over time - from 37% during first 4 infusions to 16% during last 4 infusions 3
Systemic mild reactions include:
- Flu-like symptoms: fever, chills, fatigue 1
- Headache (18.6% in adults) 3
- Myalgia and malaise 2, 4
- These are self-limiting and can be reduced by slowing infusion rate 1
Moderate Side Effects (Common: ~6% of patients)
These occur during or shortly after infusion:
- Joint pain, diarrhea, dizziness 2
- Dermatological effects: eczema, papules, urticaria 1
- Back and abdominal pain, nausea, vomiting (within first 10 minutes) 2
- Drowsiness, pruritis, rash, perspiration, vasodilation 2
- Skin lesions typically occur within 2 weeks and can be managed with corticosteroids 1
Severe Side Effects (Rare: ~1% of patients)
Immediate severe reactions:
Anaphylaxis and anaphylactoid reactions - symptoms include flushing, facial swelling, dyspnea, cyanosis, anxiety, hypotension, loss of consciousness, and potentially death 2
Hypotension and arrhythmias (including supraventricular tachycardia) 1
Transfusion-Related Acute Lung Injury (TRALI) - manifests within 6 hours with pulmonary edema and acute respiratory distress; has high mortality 1
Delayed severe reactions (<1% of patients):
Aseptic Meningitis Syndrome (AMS) 2
- Begins within hours to 2 days after treatment
- More frequent with high-dose therapy (2 g/kg body weight)
- Characterized by: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, vomiting
- Discontinuation results in remission within days without sequelae 2
Renal dysfunction including acute renal failure 2, 5
- Can result from transient ischemia or acute tubular obstruction 1
Thrombosis - veins, intracranial vessels, arteries leading to stroke or myocardial infarction 1
- Critical finding: SCIG has significantly lower thromboembolic risk (0.14 per 100 patient-years) compared to IVIG (1.8 per 100 patient-years) 6
- Especially after high-dose IVIG infusions
- Rare in replacement therapy 7
Neurological: posterior reversible encephalopathy syndrome 1
Hematological: neutropenia 1
Route-Specific Differences
IVIG has higher rates of:
- Systemic adverse reactions 1
- Thromboembolic complications 6
- Severe reactions requiring hospitalization 4
SCIG has:
- Predominantly mild local reactions (73% of patients experience local reactions) 3
- Fewer systemic reactions 1, 8
- Enhanced safety profile - only 3 thromboembolic events documented in SCIg cohorts, all in patients with pre-existing prothrombotic risk factors 6
- Improved treatment satisfaction 8
Risk Factors for Serious Complications
High-risk patients include those with:
- Multiple cardiovascular risk factors 9
- Pre-existing renal failure 9
- Elderly age 9
- Selective IgA deficiency with anti-IgA antibodies (risk of anaphylaxis) 2
- Paraproteins and cardiovascular disease (increased thrombosis risk) 7
Prevention Strategies
To minimize adverse effects:
Infusion rate management: Slow infusion rate for mild reactions 1
Premedication (only for selected high-risk patients, not routine):
Dose adjustment: Reduce from standard 1g/kg to 0.4g/kg if reactions occur 1
Product switching: Different IVIG products contain varying concentrations of IgA, sugars, amino acids, and sodium 1
Route switching: Consider SCIG for patients with recurrent IVIG reactions 4
Patient monitoring: Most reactions occur within first 6 hours (75.2% are early reactions) 10
Special Considerations
Infectious agent transmission risk: Although stringent controls are applied, the potential for transmission of viruses and theoretically CJD/vCJD agents cannot be totally excluded 2, 5
Pregnancy and lactation: Safety data limited; use only if clearly needed 2
Vaccine interference: May interfere with live virus vaccines (measles, mumps, rubella, varicella) 5, 3